---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-031856"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T01:56:09.170653+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Genprex reports positive preclinical data for Reqorsa in ALK+ NSCLC at AACR-NCI-EORTC

## Summary
- REQORSA overexpressed TUSC2 tumor suppressor gene in ALK-EML4+ NSCLC cell lines and patient derived organoids.
- Treatment induced apoptosis in ALK+ cells, including those resistant to alectinib; combination with alectinib further increased apoptosis.
- In mouse xenograft model, REQORSA + alectinib improved survival vs control, suggesting potential for future clinical trial.
- Data presented at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

## SEC filing metadata
- accession: 0001437749-25-031856
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774925031856/0001437749-25-031856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774925031856/gnpx20251024c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-031856
- JSON: https://secwatch.observer/filing/0001437749-25-031856.json
- Plain text: https://secwatch.observer/filing/0001437749-25-031856.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.